5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy

Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy

Core Clinical Principle: Profound bone marrow aplasia following conditioning chemotherapy and total body irradiation creates a period of extreme vulnerability to life-threatening bacterial infections. Because neutropenic patients lack the circulating white blood cells required to mount classic inflammatory signs (such as purulent exudate, swelling, or localized erythema), fever is frequently the sole presenting sign of overwhelming sepsis. Rapid diagnostic triage, strict adherence to the 60-minute "door-to-needle" empiric antibiotic bundle, and systematic escalation protocols are essential to prevent fatal septic shock.

---

1. Overlapping Phases of Post-Transplant Infection Risk

Calendar phases organize study but do not predict an individual infection. Pre-engraftment risk is driven by neutropenia, central access and mucosal injury, favoring bacterial infection, Candida, HSV and molds with prolonged neutropenia. Early after engraftment, T-cell dysfunction, GVHD therapy and viral reactivation become prominent; CMV, EBV, HHV-6, adenovirus, PJP and molds are considered by platform and prophylaxis. Later, chronic GVHD, immunosuppression, delayed B/T-cell recovery and functional asplenia can sustain risk from VZV, respiratory viruses, molds, PJP and encapsulated bacteria. Reclassify risk whenever counts, immune therapy, GVHD, graft function or exposure changes.

2. Neutropenic Fever: Diagnostic Criteria & Sepsis Pathophysiology

Official Consensus Definitions (IDSA / ASCO / ASTCT)

1. Fever Threshold:
   • A single oral temperature measurement >= 38.3°C (101.0°F), OR
   • A sustained temperature >= 38.0°C (100.4°F) lasting for >= 1 continuous hour.
2. Neutropenia Threshold:
   • An Absolute Neutrophil Count (ANC) < 500/mcL (0.5 x 10^9 / L), OR
   • An ANC currently < 1,000/mcL that is expected to drop below 500/mcL within the subsequent 48 hours based on conditioning chemotherapy kinetics.

$\text{ANC (cells/mcL)} = \text{Total WBC (cells/mcL)} \times \frac{\% \text{ Segmented Neutrophils (Polys)} + \% \text{ Band Neutrophils}}{100}$

Clinical Presentation in Aplasia

In the absence of mature neutrophils, the normal signs of localized inflammation are absent. Local inflammation may be muted, and fever may be the only early clue to serious infection. Bedside assessment should also look for subtle systemic warning signs:

• Unexplained resting tachycardia (heart rate > 100 bpm) or tachypnea (respiratory rate > 20 bpm).
• Mild localized tenderness or subtle erythema at the central line insertion or tunnel site.
• New-onset shivering, shaking rigors, or profuse diaphoresis.
• Sudden hypothermia (temperature < 36.0°C / 96.8°F), which signifies severe endotoxemic septic shock and peripheral vasoconstriction.
• New-onset confusion, cognitive blunting, lethargy, or acute agitation.

---

3. Emergency Triage and Prompt Antibiotics

Treat febrile neutropenia as an emergency. Assess airway, breathing, circulation, mental status, perfusion, oxygen need, line/skin/oral/perianal findings without traumatic rectal examination, and sepsis severity. Obtain central-lumen and peripheral cultures as indicated if doing so does not delay therapy; add urine, respiratory, stool, wound or imaging studies from symptoms rather than routinely ordering every test.

Administer the protocol-selected IV antipseudomonal beta-lactam promptly—many programs target within 60 minutes of recognition. Dose for renal/hepatic function and allergy and use local susceptibility data. For shock/hypoperfusion, use the sepsis pathway with individualized crystalloid boluses, early vasopressors when indicated, and frequent reassessment of perfusion and fluid tolerance; lactate 2 mmol/L alone does not impose a fixed 30 mL/kg order.

4. Empiric Antimicrobial Selection

Initial therapy must cover Pseudomonas and other likely gram-negative pathogens. Cefepime, piperacillin-tazobactam or an antipseudomonal carbapenem are common inpatient options, selected by allergy, organ function, clinical source, prior cultures/colonization, prophylaxis exposure and local susceptibility. Verify dose and infusion strategy from the current order set. Carbapenems are generally reserved for instability or resistant-organism risk rather than used automatically for every fever.

For a severe immediate beta-lactam allergy, follow the allergy pathway; aztreonam plus an anti-gram-positive agent is one common approach, but ceftazidime side-chain history, resistant organisms and clinical source matter. Allergy assessment or supervised challenge may expand options when clinically appropriate.

5. When to Add Gram-Positive Coverage

Do not add vancomycin solely for fever. Consider it or another targeted agent for hemodynamic instability, pneumonia, clinically apparent catheter or skin/soft-tissue infection, gram-positive organisms on preliminary culture, or relevant resistant-organism colonization. Severe mucositis plus fluoroquinolone exposure may influence the plan. Reassess promptly and de-escalate when cultures and clinical findings do not support continued coverage. Agent choice and exposure monitoring account for renal function, lung source, cytopenias and resistance.

6. Persistent or Breakthrough Fever

Persistent fever does not by itself prove antibacterial failure. Repeat the bedside/source assessment, culture when indicated, review line/device and drug exposure, and assess resistant bacteria, C. difficile, respiratory viruses, fungal disease and noninfectious causes. New instability or a documented organism drives immediate escalation. In a stable high-risk patient with prolonged neutropenia, use CT, galactomannan/beta-D-glucan or other diagnostics and select empiric versus preemptive antifungal therapy from prior prophylaxis, local epidemiology and organ function.

7. Antibacterial Prophylaxis

Fluoroquinolone prophylaxis may be used for patients expected to have profound, prolonged neutropenia, but selection depends on local resistance, prior colonization/infection, QT and tendon/aortic/neurologic risks, renal function, interactions, C. difficile risk and the transplant protocol. Agent, dose, start and stop dates are not determined by allogeneic versus autologous status alone. If fever develops during prophylaxis, activate the febrile-neutropenia pathway and replace prophylaxis with treatment selected for the current syndrome and exposure history rather than simply adding another oral agent.

8. Bedside Nursing Management and Infection Prevention

Use the central-line bundle, hand hygiene, oral-care plan, respiratory precautions, and food-safety teaching specified for the patient and setting. A protective environment with HEPA filtration and positive pressure is intended for defined allogeneic-HCT inpatient populations, not every autologous or cellular-therapy encounter. Avoid traumatic rectal temperatures, examinations, enemas, and suppositories during severe neutropenia, thrombocytopenia or mucositis. Manage C. difficile with soap-and-water handwashing after care and an EPA-registered sporicidal environmental product; alcohol hand rub remains useful for other indications. Reassess lines, skin, mouth, lungs, stool, urine, symptoms, cultures, organ function and antimicrobial toxicity throughout treatment.